FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to $450.9M by 2027.
SoFi Technologies Inc. (NASDAQ:SOFI) shares reversed their gains after the company reported fiscal first-quarter 2024 results on Monday. Adjusted revenue increased 26% year-on-year to $580.648 million, beating the consensus of $555.997 million. The adjusted EPS of $0.02 beat the consensus of $0.01. SoFi added 622,000 new members in the quarter, bringing its total member count to over 8.1 million (+44% Y/Y). SoFi also added over 989,000 new products in the quarter, for a total of over 11.8 millio